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ABSTRACT 
B-type natriuretic peptide (BNP) levels predict cardiovascular risk in several 
settings. We hypothesized that they would identify individuals at increased risk of 
complications and mortality following major emergency non-cardiac surgery. 
Forty patients were studied with a primary end-point of a new post-operative 
cardiac event, and/or development of significant ECG changes, and/or cardiac 
death. The main secondary outcome was all cause mortality at 6 months. Pre-
operative BNP levels were higher in 11 patients who suffered a new post-
operative cardiac event (p=0.001) and predicted this outcome with an area 
under the receiver operating characteristic curve of 0.85 (CI=0.72-0.98, 
p=0.001). A pre-operative BNP value >170pg.ml-1 has a sensitivity of 82% and a 
specificity of 79% for the primary end-point. In this small study, pre-operative 
BNP levels identify patients undergoing major emergency non-cardiac surgery 
who are at increased risk of early post-operative cardiac events. Larger studies 
are required to confirm these data. 
Word count -148 
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Major emergency surgery is associated with high levels of morbidity and morbidity [1,2]. The 
mortality from emergency laparotomy in the UK may be as high as 25% [3] and in our 
hospital carries a 12% risk of death [4]. Likewise, major emergency hip surgery is associated 
with a mortality of 9% at 30 days and 22% at 120 days [5]. Mortality in this setting may relate 
to the effects of the underlying condition or to direct effects of surgery. However, the majority 
of patients die due to the development of major cardiac complications in the early post-
operative period [1,2].  
 
Accurate pre-operative risk stratification is important for several reasons. It 
allows clinicians to explain and quantify risk and, thus, is an essential component 
in gaining informed consent. Perhaps more importantly, accurate identification of 
patients at highest risk might allow targeting of interventions that may improve 
outcome in elective or emergency surgery, such as peri-operative beta blockade 
and pre-operative optimisation [6-8]. Predicting outcome in emergency surgery 
is, however, difficult - particularly as existing risk assessment tools were 
developed and evaluated in patients undergoing major elective non-cardiac 
surgery and may lack accuracy in predicting the development of cardiac 
complications in others settings [6,9-11]. In addition, alternate methods of 
assessing cardiovascular risk - such as stress testing and/or echocardiography - 
may be impractical or difficult. The availability of a readily available 'biomarker' 
that might assist with risk stratification would, therefore, be of particular value in 
this situation. 
 
B-type natriuretic peptide (BNP) is secreted chiefly from the left ventricle in 
response to filling pressure and volume load. It promotes natriuresis, diuresis 
and vasodilatation [12]. Blood concentrations of BNP are raised in patients with 
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cardiac disease, particularly those with heart failure, though also in response to 
ischaemia. They are important markers of cardiovascular prognosis in many 
settings [13,14]. In particular, recent research suggests that pre-operative BNP 
levels are predictive of post-operative cardiac complications in patients following 
coronary artery bypass grafting [15,16]. They may also have a place in risk 
prediction before major elective non-cardiac surgery [17-20]. The utility of BNP 
in the risk stratification of patients undergoing emergency surgery has not, 
however, been previously tested. We hypothesised that pre-operative BNP would 
predict peri-operative myocardial events and / or death after surgery in patients 
undergoing major emergency non-cardiac surgery.  
 
METHODS 
The research protocol was approved by the local research ethics committee and 
written informed consent was obtained from all patients. The study was a 
prospective single centre observational cohort study of consecutive patients 
undergoing emergency major non-cardiac surgery. Major emergency non-cardiac 
surgery was defined as emergency laparotomy for gastrointestinal pathology and 
emergency hip surgery for fractured neck of femur. Emergency surgery was 
defined as surgery that requires to be performed within 24 hours of presentation.  
Pre-operative BNP sampling was undertaken after completion of pre-operative 
fluid and electrolyte resuscitation immediately before surgery.  
 
Data collection 
Pre-operative data collection included the recording of a 12 lead 
electrocardiogram (ECG), patient demographics, medical and surgical history, 
pre-operative medications, renal and hepatic function. Pre-operative blood 
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samples were also obtained for cardiac troponin I (cTnI) and plasma BNP levels. 
The Revised Cardiac Risk Index (RCRI), American Society Anesthesiology (ASA) 
score, pre-morbid New York Heart Association functional class and Canadian 
Cardiovascular Society angina score were calculated. Intra-operative data 
collection included details of surgery and anaesthesia, cardiac and non-cardiac 
complications and intra-operative inotrope requirement. Post-operative data 
collection included the recording of a 12 lead ECG and measurement of cTnI 
levels at 24 and 72 hours after surgery. Patients were followed-up while in 
hospital and vital status determined at 6 months using data provided by the 
General Register Office for Scotland. 
 
All patients were followed up by an investigator who was unaware of the 
patient’s biochemistry results and ECG outcomes. Electrocardiograms were 
analyzed by a consultant cardiologist blinded to all other data including the 
patient’s clinical status and their biochemistry results. Clinicians responsible for 
the patients’ care were blinded to the ECG and cTnI results that were obtained 
for research purposes. They were blinded to BNP results at all times.  
 
Study end-points  
The primary endpoint was the predictive power of BNP for a major adverse post 
operative cardiac event. This was defined as: cardiac death during the index 
admission and/or new post-operative myocardial injury (cTnI ≥0.1ng.ml-1 at 24 
and/or 72 hours with undetectable pre-operative levels) and/or the development 
of clinically significant new post-operative ECG changes, within 72 hours of 
surgery. 
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We have used the terminology myocardial ‘injury’ instead of ‘infarction’ as the 
latter is difficult to define in this setting [21-29]. For the purposes of this study 
acute peri-operative myocardial injury was defined as evidence of myocardial cell 
necrosis (cTnI ≥0.1ng.ml-1 – the local lower limit of detection of the assay used). 
Clinically significant ECG changes were prospectively defined as- 
a) the development of changes suggestive of significant acute myocardial 
ischemia / infarction: the development of new, post-operative, T-wave 
inversion ≥2mm and / or ST segment deviation ≥2mm in at least two-
contiguous chest leads or 1mm in at least two contiguous limb leads and / or  
b) the development of new sustained abnormal cardiac rhythm within 72 hours 
of surgery. 
 
The following secondary end-points were also assessed: 
a) new post-operative myocardial injury (defined as above), within 72 hours of 
surgery 
b) any post-operative myocardial injury (cTnI ≥0.1ng.ml-1 at 24 and/or 72 hours 
regardless of pre-operative levels) 
c) all-cause mortality 6 months after surgery 
 
Assays 
Blood was collected in EDTA and lithium heparin Vacutainer™ tubes, which were 
then immediately centrifuged with plasma stored at –80°C for later analysis. 
Prior to the pre-operative blood sample, patients were asked to lie quietly in the 
supine position for 30 minutes in order to eliminate any possible confounding 
effects of posture and exercise on plasma BNP levels. BNP and cTnI assays were 
measured using the Bayer ADVIA Centaur™ immunoassay analyser [30,31]. The 
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lower limit of detection for BNP is 2pg.ml-1 and the coefficients of variation at 
29.4pg.ml-1 and 410pg.ml-1 are 4.7% and 2.8% respectively [30,31].  
 
Statistics  
Data was analysed on Statistics Package for Social SciencesTM 12 software. 
Categorical data are presented as absolute values and percentages. Normally 
distributed continuous variables are expressed as mean and standard deviation, 
while those with a skewed distribution are expressed as median and interquartile 
range. Fisher’s exact test was used to test differences between independent 
categorical data. Differences between two independent groups of continuous data 
were tested using the Mann-Whitney U test. Receiver Operating Characteristic 
curves were plotted and the area under the curve estimated. Backward 
conditional logistic regression analysis was used to test the independent 
predictive value of elevated BNP levels. A p value <0.05 was considered 
significant. 
 
RESULTS 
Fifty-eight patients met inclusion criteria for the study and were invited to 
participate. Forty-six patients (79%) consented to the study and 40 underwent 
surgery and completed the trial protocol. Baseline data are presented in table 1.  
 
The median pre-operative BNP level was 100pg.ml-1 (62-205), rising at 24 hours 
to 157pg.ml-1 (82-225: p=0.07 v baseline) and falling by 72 hours post-
operatively to 72pg.ml-1 (41-167: p=0.001 v baseline). Fifteen patients had 
detectable (≥0.1ng.ml-1) levels of cTnI pre-operatively. In six of these subjects 
levels fell below 0.1ng.ml-1 post-operatively, whereas an additional 5 patients 
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exhibited de novo elevation. Six further patients developed significant new 
changes on their post-operative ECG(s). One patient died 4 days after surgery 
due to acute myocardial infarction, there were no other deaths within the first 28 
days. A further 5 patients died during follow-up, resulting in a total of 6 deaths 
(15%) at 6 months. 
 
Pre-operative BNP levels in patients were significantly higher among patients 
who experienced a post-operative cardiac event (table 1 and figure 1). Patients 
who exhibited new post-operative myocardial damage (elevation of cTnI 
≥0.1ng.ml-1 at 24 and/or 72 hours with normal pre-operative levels: n=5) had a 
median pre-operative BNP of 201pg.mL-1 (135-407) compared to 88pg.mL-1 (59-
194) in patients without de novo cTnI release (p=0.07). Likewise, median pre-
operative BNP levels among patients with any post-operative myocardial damage 
(cTnI ≥0.1ng.ml-1 at 24 and/or 72 hours regardless of pre-operative levels: 
n=14) were 214pg.mL-1 (89-433) compared to 83pg.mL-1 (52-144; p=0.005) 
among those patients who did not have any cTnI elevation after surgery. 
 
Median pre-operative BNP levels were 196 pg.mL-1 [96-296] in the 6 patients 
who died during 6 month follow-up (v 88pg.mL-1 [57-201] among survivors: 
p=0.10). Pre-operative cTnI levels were 0.00ng.mL-1 [0.00-0.13] in surviving 
patients (v 0.1ng.mL-1 [0.00-0.52] in those that died) (p=0.38). However, 
neither elevated (≥0.1 ng.ml-1) pre-operative or post-operative cTnI levels 
predicted 6-month mortality (p=0.65 for both). 
 
Pre-operative BNP predicted the primary outcome with an area under the 
receiver operator characteristic curve of 0.85 (95% confidence interval [CI] 0.72-
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0.98, p=0.001). The optimal cut-point derived from this curve was 170pg.ml-1. 
This has a sensitivity of 82% and a specificity of 79% (Figure 2). Pre-operative 
BNP levels ≥170pg.mL-1 predicted the primary outcome with an odds ratio (OR) 
of 17.3 (95% CI 2.9-101.9, p=0.002). 
 
Relative utility of BNP and existing risk prediction scores 
Patients with an RCRI of 1 or 2 had a BNP of 83pg.mL-1 (56–191) compared to 
195pg.mL-1 (121–466: p=0.02) in those with a RCRI of 3 and 4. Likewise, 
patients with ASA scores of 1 and 2 had a median BNP of 83pg.mL-1 (63–154) 
compared to 183pg.mL-1 (60–356: p=0.12) in those with an ASA score of 3 to 5. 
 
When pre-operative BNP levels (as a continuous variable) were included in a 
multivariable model along with the pre-operative ASA score and the RCRI the 
only independent predictor of the primary outcome was the ASA score (OR 4.78 
per unit increase, 95% CI 1.48-15.39, p=0.009). There was, however, a trend 
for BNP to provide additional independent prognostic information (OR 1.04 per 
10pg.mL-1 increase, 95% CI 1.00-1.08, p=0.07). In a second model including the 
ASA score, the RCRI and BNP levels dichotomised around the optimal cut-off, the 
independent predictors were BNP ≥170pg.mL-1 (OR 13.6, 95% CI 1.9-97.8, 
p=0.009) and the RCRI (OR 2.8 per unit increase, 95% CI 1.2-6.9, p=0.02).
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DISCUSSION 
Patients undergoing major emergency surgery are at high risk of peri-operative 
cardiovascular complications. However, within this population the magnitude of 
this hazard will vary. Paradoxically, these patients are least likely to undergo 
formal risk-stratification. This, at least in part, reflects the imperative for surgery 
and the absence of evidence-based interventions to reduce complications. It may 
also be due to the difficulty in performing specialist investigations, plus the lack 
of well-validated and easily applied methods of estimating risk in this setting. 
Some of these reasons, in turn, reflect the paucity of research in such acutely ill-
patients - who are less easy to identify and enrol into trials than those 
undergoing elective surgery. 
 
The current study suggests that pre-operative BNP levels are higher in patients 
who suffer an early post-operative cardiac event and may provide prognostic 
information that is incremental to existing methods of risk-prediction such as the 
ASA score and the RCRI. Pre-operative BNP also shows a trend towards 
predicting 6-month mortality.  
 
Prior studies 
There are no prior data addressing the role of BNP in predicting outcome from 
emergency non-cardiac surgery. However, several recent reports have suggested 
that BNP or N terminal pro-BNP levels are useful in pre-operative risk-
stratification in elective non-cardiac surgery [17-19]. In this setting BNP and N 
terminal pro-BNP identify patients at risk of per-operative myocardial damage 
and heart failure. In addition, BNP predicts medium term mortality in this group 
[20]. There is also a growing body of literature suggesting a prognostic role for 
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BNP and its derivatives at the time of cardiac surgery [15,16]. In contrast, the 
role of BNP in predicting risk associated with critical illness is less clear [32-34]. 
 
There are a variety of mechanisms whereby BNP might predict risk in this 
setting. BNP is often considered a global marker of cardiac function or health. In 
patients with symptomatic heart disease natriuretic peptide levels are markers of 
increased myocardial stress, usually from volume and pressure overload but also 
in response to hypoxia and ischaemia [35,36]. Levels of BNP predict cardiac 
events, such as incident myocardial infarction and death, in many settings - 
including patients with heart failure, stable coronary heart disease and even in 
apparently healthy populations [14]. Many patients presenting for major surgery 
may have clinical or subclinical cardiac failure or ischaemic heart disease. Pre-
operative BNP levels will reflect their underlying cardiovascular status, identifying 
those with a reduced cardiac reserve - who present a greater risk of peri-
operative myocardial infarction and early and late mortality [37-39].  
 
Other methods of risk stratification 
The practicalities of risk-stratification in emergency surgery have been 
mentioned above. Existing risk prediction scores such as the ACC/AHA and 
Revised Cardiac Risk Index have limited clinical utility and are not commonly 
applied in everyday practice [9-11]. Further, these scores may have a limited 
role in emergency surgery patients as they have been derived in cohorts 
undergoing elective major non-cardiac surgery. Given these limitations, a rapid 
and relatively cheap biochemical test, potentially available by near patient 
testing, with a clearly defined cut point, would be of considerable clinical utility.   
 
 13 
Limitations 
This was a small study with limited power. In addition, the requirement to gain 
informed consent meant that patients with low mental state questionnaire scores 
were excluded. As these patients often have the highest operative risk, this may 
have introduced a degree of bias into our sample. Acute illness and fluid 
imbalance may also affect BNP levels. We attempted to allow for this by 
measuring BNP after pre-operative resuscitation was complete. However this 
time point is imprecise and the exact fluid status of the patient at time of 
sampling is uncertain. Finally, our cohort is heterogenous - including patients 
undergoing major emergency abdominal and hip surgery. Nevertheless, if BNP 
levels were to prove clinically useful they would have to demonstrate sensitivity 
and specificity in such diverse clinical situations. 
 
In a small study we were able to show that elevated pre-operative BNP levels 
were associated with an increased risk of early post-operative cardiac events in 
patients undergoing major emergency non-cardiac surgery. Further work is 
required to clarify the role of BNP in this setting. 
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Table 1. Baseline clinical characteristics of the study cohort. 
 
Patient 
Characteristic 
Patients with 
post-operative 
cardiac event* 
(n = 11) 
Patients without 
post-operative 
cardiac event* 
(n = 29) 
P-
value 
Male  15 (38) 3 (27) 12 (41) 0.48 
Age 74 (64-83) 80 (69-85) 73 (62–80) 0.08 
Diabetes 4 (10) 3 (27) 1 (3) 0.06 
Hypertension 20 (50) 8 (73) 12 (41) 0.08 
Previous MI 8 (20) 6 (55) 2 (7) 0.003 
MI <6 months ago 0 0 0 - 
Angina 9 (23) 5 (45) 4 (14) 0.05 
Atrial fibrillation 4 (10) 0 4 (14) 0.26 
Current smoker: 11 (28) 1 (9) 10 (35) 0.11 
Previous CABG or PCI 5 (13) 3 (27) 2 (7) 0.12 
Previous major non-cardiac 
surgery 
12 (30) 4 (36) 8 (28) 0.43 
Cardiac medication 23 (58) 9 (82) 14 (48) 0.06 
Chronic beta blockade 8 (20) 3 (27) 5 (17) 0.38 
Peri-operative beta blockade 0 0 0 - 
CCS angina status 0.48 ±1.01 1.09 ±1.51 0.24 ±0.64 0.03 
NYHA functional class 1.23 ±0.58 1.55 ±0.93 1.10 ±0.31 0.12 
RCRI score 1.68 ±1.02 2.55 ±1.29 1.34 ±0.67 0.004 
ASA score 2.70 ±0.88 3.45 ±0.82 2.41 ±0.73 0.001 
Creatinine (µmol/L) 85 (69-107) 87 (69-179) 84 (69-104) 0.29 
BNP (pg.ml-1) 100 (62–205) 310 (177–443) 82 (51–149) 0.001 
cTnI (ng.ml-1) 0.00 (0.00-0.16) 0.12 (0.10 – 0.43) 0.00 (0.00– 0.12) 0.13 
Surgical procedure     
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    Hip surgery 23 7 16  
     Laparotomy 17 4 13 0.73 
Anaesthesia     
     General† 25 7 18  
     Regional† 13 4 9 1.00 
 
Variables presented as medians and interquartile ranges or as number and 
percentages. 
 
* post-operative cTnI ≥0.10ng.ml-1 (where pre-operative cTnI < 0.10ng.ml-1), 
and/or development of significant ECG changes (see text for details), and/or 
death. 
† two patients had both regional and general anaesthesia  
 
MI = myocardial infarction; PCI = percutaneous coronary intervention; CABG = 
coronary artery bypass grafting; RCRI = revised cardiac risk index; ASA = 
American Society of Anesthesiologists grading; BNP = B-type natriuretic peptide; 
cTnI = cardiac troponin I. 
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Figure 1. A comparison of pre-operative BNP levels in patients who experienced 
a post-operative cardiac event against those who did not.  
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Central lines represent medians, boxes 25th and 75th centiles and whiskers 
represent ranges.  
 
p = 0.001 
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Figure 2. Receiver operator characteristic curve for pre-operative BNP levels 
predicting an early post-operative cardiac event. 
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Area under the curve = 0.85 (95% CI=0.72-0.98, p=0.001). 
 
